Ced Service GmbH
5
1
1
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 85/100
20.0%
1 terminated/withdrawn out of 5 trials
0.0%
-86.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (5)
Efficacy and Safety of Oral Controlled-Ileocolonic-Release Nicotinamide (CICR-NAM) in Patients with Mild to Moderately Active Ulcerative Colitis
Role: collaborator
Tofacitinib Registry of Patients With Ulcerative Colitis in Germany
Role: lead
TARGET Registry A Project of the German Network for Intestinal Diseases in Cooperation With Other Corporate Partners
Role: lead
Real World Effectiveness of Ustekinumab in Induction and Maintenance Therapy for Crohn´s Disease
Role: lead
Vedolizumab Study With Inflammatory Bowel Disease Patients in Germany
Role: lead
All 5 trials loaded